Merck & Co., Inc. vs Samumed
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
Market cap history
● Merck & Co., Inc.● Samumed
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Merck & Co., Inc. MRK · #40 in the world | Samumed |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | — |
| Founded | 1970 | 2008 |
| Size | ||
| Market cap | $359.8 B | — |
| Revenue | $65.0 B | — |
| Net income | $18.3 B | — |
| Employees | 75,000 | — |
| Valuation | ||
| P/E ratio | 147× | — |
| Price to sales | 5.3× | — |
| Price to book | 6.8× | — |
| Free cash flow yield | 3.4% | — |
| Profitability | ||
| Gross margin | 74.8% | — |
| Net margin | 28.1% | — |
| Return on equity | 36.9% | — |
| Growth | ||
| Revenue growth | 1.3% | — |
| Revenue growth, 3 years a year | 3.1% | — |
| Earnings per share growth | 8.0% | — |
| Financial strength | ||
| Debt to equity | 0.9× | — |
| Cash | ||
| Free cash flow margin | 19.0% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 3.7% | — |
| Strength scores | ||
| Piotroski F-score | 4 of 9 | — |
| Altman Z-score zone | — | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap — |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
More about Merck & Co., Inc.
More about Samumed
Sources#
Every figure on this page comes from these, with the date shown next to it.